MedPath

Indocyanine green and infrared fluorescence in sentinel lymph node mapping for endometrial cancer and cervical cancer: An exploratory study

Phase 2
Conditions
Endometria cancer, Cervical cancer
Registration Number
JPRN-jRCTs031180426
Lead Sponsor
sui Hirokazu
Brief Summary

The study was terminated before the targeted initial sample size. The detection rate of sentinel lymph nodes in this study was about 80.4% and 95%CI. The negative predictive value was 100%. There was no adverse event according to the injection of ICG. Although the number of cases was small, the negative predictive value was 100%, suggesting that lymph node dissection may be omitted in cases with negative sentinel lymph nodes.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Female
Target Recruitment
46
Inclusion Criteria

1. Patients with endometrial cancer who are scheduled for retroperitoneal lymph node dissection or patients with stage 1A2 to 2A1 cervical cancer based on the International Federation of Gynecology and Obstetrics guidelines.
2. Over 20 years of age and under 70 years of age
3. Eastern Cooperative Oncology Group Performance status score 0-1
4. Patients who provide written informed consent

Exclusion Criteria

1.Prior medical history of chemical sensitivity to indocyanine green
2.Detection of obvious lymph node swelling using CT or MRI
3.Extra-uterine dissemination
4.Patients on dialysis
5.Patients determine to be ineligible for any other reason by the physician in-charge

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The detection rate of S
Secondary Outcome Measures
NameTimeMethod
1.The sensitivity of sentinel lymph node (SLN)<br>2 A false negative rate of SLN<br>3. Negative predictive value of SLN<br>4. The accuracy of pathological diagnosis during surgery<br>5. The number and location of the SLNs<br>6. Adverse effects
© Copyright 2025. All Rights Reserved by MedPath